Please login to the form below

Not currently logged in
Email:
Password:

New member for Baxterís board of directors

Baxter International has elected Dr Wayne T Hockmeyer to serve as a member of its board of directors from September 2007

Baxter International has elected Dr Wayne T Hockmeyer to serve as a member of its board of directors from September 2007.

Hockmeyer founded MedImmune and served as its CEO and chairman from 1988 to 2000. MedImmune develops therapies for infectious disease, inflammatory disease and cancer and was recently acquired by AstraZeneca.

"Wayne is an exciting addition to our board of directors and we welcome the strong executive, scientific and operational experience he brings," said Robert L. Parkinson, Jr., Baxter's chairman and chief executive officer. "His extensive scientific and R&D expertise will be invaluable in helping Baxter achieve its innovation and growth objectives."

Before Medimmune, Hockmeyer was vice-president of laboratory research and product development at Praxis Biologics and served as chief of the department of immunology at Walter Reed Army Institute of Research.

Hockmeyer is a member of the boards of directors of Middlebrook Pharmaceuticals, GenVec and Idenix Pharmaceuticals.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics